PDCD1 and non-small cell lung carcinoma: Clinical treatment guidelines recommended platinum-based chemotherapy as first-line chemotherapy and second-line chemotherapy (docetaxel, pemetrexed) as a subsequent treatment regimen before programmed cell death-1 (PD-1)/programmed cell death receptor ligand-1 (PD-L1) inhibitors were used in the treatment of metastatic NSCLC (Ettinger et al., 2022).